Helio HemOnc Today
June 24, 2019
CHICAGO — Patients with small, node-negative, triple-negative breast cancer treated with adjuvant chemotherapy experienced improvements in OS and breast cancer specific-survival, according to a study presented at ASCO.
“International guidelines differ in their recommendation for adjuvant chemotherapy in small, node-negative, triple-negative breast cancer,” Tessa GerjanneSteenbruggen, MD, of the department of medical oncology at the Netherlands Cancer Institute and colleagues wrote. “We evaluated associations of chemotherapy with long-term outcome in a large, population-based, triple-negative breast cancer cohort.”
Steenbruggen and colleagues used the Netherlands Cancer Registry to identify 4,393 patients who received a diagnosis of pT1N0M0 triple-negative breast cancerbetween 2005 and 2015, 284 of whom had T1a, 924 had T1b and 3,185 had T1c tumors.
The researchers documented patient, tumor and therapy traits. Data from Statistics Netherlands were used to determine date and cause of death. They also performed multivariable Cox regression models to assess how chemotherapy affects OS and breast cancer-specific survival while adjusting for baseline characteristics. Tumor size and grade were considered in subgroup evaluations.
Read the Full Article Here:
Reference:
Steenbruggen TG, et al. Abstract 536. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Disclosure: Steenbruggen reports no relevant financial disclosures. Please see abstract for all other authors’ relevant financial disclosures.